Alltrna Stock / BioTech & PharmaFounded: 2018

Alltrna, founded in 2018, is a biotechnology company that works with tRNA that strives to address and treat genetic diseases. Alltrna is using AI and machine learning with the goal of better understanding how tRNA translates the information from the DNA. They use that information to generate programmable tRNA molecules that translate the incorrect information from the DNA and results in the production of healthy proteins to treat genetic disease. Alltrna is headquartered in Cambridge, Massachusetts.

Register for Details

For more details on financing and valuation for Alltrna, register or login.

Please provide a valid email address.

By registering, you agree to Forge’s Terms of Use. Already registered? Log in


Enterprise Value (based on primary financings)

Powered by Forge Data
Enterprise Value

View Enterprise Value for Alltrna.

Register Today

Alltrna investors also invested in these private companies


Management Team

Michelle Werner
Co-Chief Executive Officer
Joanne Protano
Chief Financial Officer
Lovisa Afzelius Ph.D
Co-Founder & Co-Chief Executive Officer
Theonie Anastassiadis Ph.D
Co-Founder & Chief Innovation Officer
Noubar Afeyan Ph.D

Other companies like Alltrna in the BioTech & Pharma sector

Last Round Est. Valuation
Last Round Est. Valuation
Last Round Est. Valuation
Last Round Est. Valuation
Last Round Est. Valuation
Last Round Est. Valuation
Last Round Est. Valuation

News Highlights

Flagship's Alltrna collects $109M as it passes go to Stop Codon Disease
Alltrna has raised another $109 million in a series B to fund the Flagship Pioneering biotech's mission to "stop codon disease" with potential benefits for a range of genetic diseases caused by premature termination codon mutation.
Updated on: Oct 3, 2023


Public news articles listed on this page have been curated by Forge based on several factors including, but not limited to, product updates, changes in organization structure, funding rounds, third-party valuations, and key personnel changes. Changes to this list of articles can be made at any time without notice and should not be relied upon for investment purposes. Forge does not verify the accuracy of the information contained in public news articles.